Samuel D Vasikaran

List of Publications by Year
in descending order

119	5,317	117453	85405
papers	citations	34 h-index	71 g-index

120	120	120	5283
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Practical Considerations for the Clinical Application of Bone Turnover Markers in Osteoporosis. Calcified Tissue International, 2023, 112, 148-157.	1.5	16
2	Comparison of four indirect (data mining) approaches to derive within-subject biological variation. Clinical Chemistry and Laboratory Medicine, 2022, .	1.4	5
3	Comparison of 8 methods for univariate statistical exclusion of pathological subpopulations for indirect reference intervals and biological variation studies. Clinical Biochemistry, 2022, 103, 16-24.	0.8	9
4	The Role of PINP in Diagnosis and Management of Metabolic Bone Disease. , 2021, 42, 3-10.		14
5	Analytical Performance Specifications for 25-Hydroxyvitamin D Examinations. Nutrients, 2021, 13, 431.	1.7	13
6	A Multicenter Study to Evaluate Harmonization of Assays for C-Terminal Telopeptides of Type I Collagen (ÃŸ-CTX): A Report from the IFCC-IOF Committee for Bone Metabolism (C-BM). Calcified Tissue International, 2021, 108, 785-797.	1.5	9
7	Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and Î²-CTX in blood. Clinica Chimica Acta, 2021, 515, 16-20.	0.5	31
8	The path to the standardization of PTH: Is this a realistic possibility? a position paper of the IFCC C-BM. Clinica Chimica Acta, 2021, 515, 44-51.	0.5	14
9	Recommendations on the measurement and the clinical use of vitamin D metabolites and vitamin D binding protein â€“ A position paper from the IFCC Committee on bone metabolism. Clinica Chimica Acta, 2021, 517, 171-197.	0.5	33
10	Interpretative commenting in clinical chemistry with worked examples for thyroid function test reports. Practical Laboratory Medicine, 2021, 26, e00243.	0.6	1
11	Harmonization of commercial assays for PINP; the way forward. Osteoporosis International, 2020, 31, 409-412.	1.3	13
12	Short- and long-term biological variation of cardiac troponin I in healthy individuals, and patients with end-stage renal failure requiring haemodialysis or cardiomyopathy. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1941-1949.	1.4	5
13	Bone turnover marker monitoring in osteoporosis treatment response. European Journal of Endocrinology, 2020, 183, C5-C7.	1.9	10
14	A multicenter study to evaluate harmonization of assays for N-terminal propeptide of type I procollagen (PINP): a report from the IFCC-IOF Joint Committee for Bone Metabolism. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1546-1555.	1.4	25
15	Highâ€Sensitivity Cardiac Troponin I Improves Cardiovascular Risk Prediction in Older Men: HIMS (The) Tj ETQq1 1 0.784314 rgBT /Ov	1.6	12
16	The challenge of improving the diagnostic yield from metanephrine testing in suspected phaeochromocytoma and paraganglioma. Annals of Clinical Biochemistry, 2018, 55, 679-684.	0.8	4
17	Assessment of bone turnover in osteoporosis: harmonization of the total testing process. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1603-1607.	1.4	10
18	Clinical utility of bone turnover markers in the management of common metabolic bone diseases in adults. Clinica Chimica Acta, 2018, 481, 161-170.	0.5	25

#	Article	IF	Citations
19	Improved technical success and radiation safety of adrenal vein sampling using rapid, semi-quantitative point-of-care cortisol measurement. Annals of Clinical Biochemistry, 2018, 55, 588-592.	0.8	25
20	Bone Turnover Markers. , 2018, , 116-127.		2
21	Faecal Calprotectin. Clinical Biochemist Reviews, 2018, 39, 77-90.	3.3	30
22	Clinical usefulness of bone turnover marker concentrations in osteoporosis. Clinica Chimica Acta, 2017, 467, 34-41.	0.5	96
23	Impact of the Australian gender specific thresholds using the Abbott high sensitivity troponin I assay in clinical care. Pathology, 2017, 49, 514-517.	0.3	2
24	Bone turnover markers: Defining a therapeutic target. Clinical Biochemistry, 2017, 50, 162-163.	0.8	8
25	Measurement and Clinical Utility of Î²CTX in Serum and Plasma. Advances in Clinical Chemistry, 2017, 81, 97-134.	1.8	4
26	Clinical Utility and Measurement of Procalcitonin. Clinical Biochemist Reviews, 2017, 38, 59-68.	3.3	74
27	Assuring the quality of interpretative comments in clinical chemistry. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1901-1911.	1.4	49
28	Comparison of clinical cut-points and treatment targets for urine NTX and plasma Î²CTX-I in osteoporosis. Clinical Biochemistry, 2016, 49, 529-533.	0.8	9
29	25-Hydroxyvitamin D C3-epimer is universally present in neonatal Western Australian samples but is unlikely to contribute to diagnostic misclassification. Annals of Clinical Biochemistry, 2016, 53, 593-598.	0.8	22
30	The use of biochemical markers of bone turnover in the clinical management of primary and secondary osteoporosis. Endocrine, 2016, 52, 222-225.	1.1	34
31	Is vitamin D testing at a tertiary referral hospital consistent with guideline recommendations?. Pathology, 2015, 47, 335-340.	0.3	4
32	Reference Intervals for Bone Turnover Markers and Their Association With Incident Hip Fractures in Older Men: The Health In Men Study. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 90-99.	1.8	48
33	Anatomy and history of an external quality assessment program for interpretative comments in clinical biochemistry. Clinical Biochemistry, 2015, 48, 467-471.	0.8	11
34	Comparison of results from commercial assays for plasma CTX: The need for harmonization. Clinical Biochemistry, 2015, 48, 519-524.	0.8	19
35	Towards optimising the provision of laboratory services for bone turnover markers. Pathology, 2014, 46, 267-273.	0.3	12
36	A Meta-Analysis of Reference Markers of Bone Turnover for Prediction of Fracture. Calcified Tissue International, 2014, 94, 560-567.	1.5	141

#	Article	IF	Citations
37	Outliers affecting cardiac troponin I measurement: comparison of a new high sensitivity assay with a contemporary assay on the Abbott ARCHITECT analyser. Annals of Clinical Biochemistry, 2014, 51, 476-484.	0.8	23
38	Harmonised Australian Reference Intervals for Serum PINP and CTX in Adults. Clinical Biochemist Reviews, 2014, 35, 237-42.	3.3	24
39	A diagnostic conundrum: heterophilic antibody interference in an adrenocorticotropic hormone immunoassay not detectable using a proprietary heterophile blocking reagent. Annals of Clinical Biochemistry, 2013, 50, 433-437.	0.8	20
40	The role of the laboratory in ensuring appropriate testing. Annals of Clinical Biochemistry, 2013, 50, 283-284.	0.8	0
41	Cortisol: ACTH ratio to test for primary hypoadrenalism: a pilot study. Postgraduate Medical Journal, 2013, 89, 617-620.	0.9	16
42	Highâ€sensitivity troponin in marathon runners. Medical Journal of Australia, 2013, 199, 169-170.	0.8	0
43	A high pressure liquid chromatography method for separation of prolactin forms. Annals of Clinical Biochemistry, 2012, 49, 285-288.	0.8	7
44	High-sensitivity cardiac troponin assays for risk stratification and for the diagnosis of acute myocardial infarction. Annals of Clinical Biochemistry, 2012, 49, 209-210.	0.8	7
45	Cardiac troponin testing in the acute care setting: Ordering, reporting, and high sensitivity assaysâ€"an update from the Canadian society of clinical chemists (CSCC); the case for age related acute myocardial infarction (AMI) cut-offs. Clinical Biochemistry, 2012, 45, 513-514.	0.8	18
46	The role of the laboratory in investigation and management of bone disease. Clinical Biochemistry, 2012, 45, 861-862.	0.8	2
47	Current Recommendations for Laboratory Testing and Use of Bone Turnover Markers in Management of Osteoporosis. Annals of Laboratory Medicine, 2012, 32, 105-112.	1.2	113
48	Official Positions for FRAXÂ® Clinical Regarding Biochemical Markers. Journal of Clinical Densitometry, 2011, 14, 220-222.	0.5	41
49	Standardising biochemical assessment of bone turnover in osteoporosis. Clinical Biochemistry, 2011, 44, 1033-1034.	0.8	12
50	Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporosis International, 2011, 22, 391-420.	1.3	893
51	International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine Position on bone marker standards in osteoporosis. Clinical Chemistry and Laboratory Medicine, 2011, 49, 1271-1274.	1.4	274
52	Recommendations for bone marker standards in osteoporosis: what, why and where to now?. Annals of Clinical Biochemistry, 2011, 48, 91-92.	0.8	8
53	Measuring performance. Clinical Biochemist Reviews, 2011, 32, 3-4.	3.3	4
54	Ischaemia modified albumin cannot be used for rapid exclusion of acute coronary syndrome. Emergency Medicine Journal, 2010, 27, 668-671.	0.4	8

#	Article	IF	Citations
55	An audit of management of patients with borderline increased plasma-free metanephrines. Annals of Clinical Biochemistry, 2010, 47, 554-558.	0.8	16
56	Cardiac troponin increases among marathon runners in the Perth Marathon: the Troponin in Marathons (TRIM) study. Medical Journal of Australia, 2009, 190, 91-93.	0.8	41
57	Quality of interpretative commenting on common clinical chemistry results in the Asia-Pacific region and Africa. Clinical Chemistry and Laboratory Medicine, 2009, 47, 963-70.	1.4	18
58	Should serial assessment of bone turnover markers be included in fracture risk calculation in elderly women?. Nature Clinical Practice Endocrinology and Metabolism, 2009, 5, 12-13.	2.9	2
59	Salivary paracetamol: evaluation of a colorimetric method in assessing deliberate self-poisoning. Annals of Clinical Biochemistry, 2009, 46, 149-151.	0.8	5
60	An audit of oral glucose tolerance tests at a large teaching hospital: indications, outcomes and confounding factors. Annals of Clinical Biochemistry, 2009, 46, 390-393.	0.8	5
61	Proficiency Testing of Hb A1c: A 4-Year Experience in Taiwan and the Asian Pacific Region. Clinical Chemistry, 2009, 55, 1876-1880.	1.5	4
62	Recurrent Low-Energy Femoral Shaft Fractures and Osteonecrosis of the Jaw in a Case of Multiple Myeloma Treated With Bisphosphonates. Journal of Oral and Maxillofacial Surgery, 2009, 67, 645-649.	0.5	22
63	Association of low-energy femoral fractures with prolonged bisphosphonate use: a case--control study. Osteoporosis International, 2009, 20, 1457-1458.	1.3	11
64	Serum 25-hydroxyvitamin D levels in vitamin D-insufficient hip fracture patients after supplementation with ergocalciferol and cholecalciferol. Bone, 2009, 45, 870-875.	1.4	89
65	Selective monitoring of vitamin D2 and D3 supplementation with a highly specific 25-hydroxyvitamin D3 immunoassay with negligible cross-reactivity to 25-hydroxyvitamin D2. Clinica Chimica Acta, 2009, 404, 144-148.	0.5	11
66	B-vitamins reduce plasma levels of beta amyloid. Neurobiology of Aging, 2008, 29, 303-305.	1.5	40
67	Utility of Biochemical Markers of Bone Turnover and Bone Mineral Density in Management of Osteoporosis. Critical Reviews in Clinical Laboratory Sciences, 2008, 45, 221-258.	2.7	69
68	Interpretative commenting. Clinical Biochemist Reviews, 2008, 29 Suppl 1, S99-S103.	3.3	2
69	Association of Cardiovascular Risk Factors and Disease With Depression in Later Life. American Journal of Geriatric Psychiatry, 2007, 15, 506-513.	0.6	94
70	Directions for clinical practice improvement in HFE gene mutation testing. Medical Journal of Australia, 2007, 187, 342-344.	0.8	0
71	A 20-week randomized controlled trial of estradiol replacement therapy for women aged 70 years and older: Effect on mood, cognition and quality of life. Neurobiology of Aging, 2006, 27, 141-149.	1.5	107
72	Urinary NTX results rarely alter the clinical management of patients with osteoporosis in the tertiary hospital. Pathology, 2006, 38, 49-52.	0.3	5

#	Article	IF	Citations
73	Efficacy of B Vitamins in Lowering Homocysteine in Older Men. Stroke, 2006, 37, 547-549.	1.0	31
74	Current assays overestimate 25-hydroxyvitamin D3 and underestimate 25-hydroxyvitamin D2 compared with HPLC: need for assay-specific decision limits and metabolite-specific assays. Annals of Clinical Biochemistry, 2006, 43, 23-30.	0.8	119
75	The role of biochemical markers of bone turnover in osteoporosis management in clinical practice. Clinical Biochemist Reviews, 2006, 27, 119-21.	3.3	11
76	Subjective Memory Complaints With and Without Objective Memory Impairment: Relationship With Risk Factors for Dementia. American Journal of Geriatric Psychiatry, 2005, 13, 731-734.	0.6	65
77	Contribution of the MTHFR gene to the causal pathway for depression, anxiety and cognitive impairment in later life. Neurobiology of Aging, 2005, 26, 251-257.	1.5	81
78	Subjective memory complaints with and without objective memory impairment: relationship with risk factors for dementia. American Journal of Geriatric Psychiatry, 2005, 13, 731-4.	0.6	28
79	Suboptimal management of subclinical hypothyroidism. Medical Journal of Australia, 2004, 181, 232-232.	0.8	0
80	Quality Assessment of Interpretative Commenting in Clinical Chemistry. Clinical Chemistry, 2004, 50, 632-637.	1.5	67
81	Major method-specific differences in the measurement of intact parathyroid hormone: studies in patients with and without chronic renal failure. Annals of Clinical Biochemistry, 2004, 41, 149-154.	0.8	12
82	Association Between Homocysteine, Depression, and Cognitive Function in Community-Dwelling Older Women from Australia. Journal of the American Geriatrics Society, 2004, 52, 327-328.	1.3	36
83	A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone. Bone, 2004, 34, 747-754.	1.4	83
84	Homocysteine and vitamin status in older people in Perth. Medical Journal of Australia, 2004, 180, 539-540.	0.8	6
85	Issues of methodology, standardization and metabolite recognition for 25-hydroxyvitamin D when comparing the DiaSorin radioimmunoassay and the Nichols Advantage automated chemiluminescence protein-binding assay in hip fracture cases. Annals of Clinical Biochemistry, 2003, 40, 546-551.	0.8	66
86	A discussion of cases in the 2001 RCPA-AQAP Chemical Pathology Case Report Comments Program. Pathology, 2003, 35, 145-150.	0.3	5
87	A discussion of cases in the 2001 RCPA-AQAP Chemical Pathology Case Report Comments Program. Pathology, 2003, 35, 145-150.	0.3	3
88	A discussion of cases in the 2001 RCPA-AQAP Chemical Pathology Case Report Comments Program. Pathology, 2003, 35, 145-50.	0.3	5
89	Vitamin D Status and Redefining Serum PTH Reference Range in the Elderly. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 946-947.	1.8	10
90	Cardiovascular disease and osteoporosis: is there a link between lipids and bone?. Annals of Clinical Biochemistry, 2002, 39, 203-210.	0.8	50

#	Article	IF	Citations
91	Homocysteine, folate, methylene tetrahydrofolate reductase genotype and vascular morbidity in diabetic subjects. Clinical Science, 2002, 102, 631-637.	1.8	25
92	Homocysteine, folate, methylene tetrahydrofolate reductase genotype and vascular morbidity in diabetic subjects. Clinical Science, 2002, 102, 631.	1.8	18
93	Surgically correctable hypertension. Pathology, 2002, 34, 297-298.	0.3	4
94	The VITATOPS (Vitamins to Prevent Stroke) Trial: Rationale and Design of an International, Large, Simple, Randomised Trial of Homocysteine-Lowering Multivitamin Therapy in Patients with Recent Transient Ischaemic Attack or Stroke. Cerebrovascular Diseases, 2002, 13, 120-126.	0.8	138
95	Preanalytical Factors in the Measurement of Intact Parathyroid Hormone with the DPC IMMULITE Assay. Clinical Chemistry, 2002, 48, 566-567.	1.5	24
96	Parathyroid Hormone Is More Stable in EDTA Plasma Than in Serum. Clinical Chemistry, 2002, 48, 766-767.	1.5	39
97	Decision limit for troponin I and assay performance. Annals of Clinical Biochemistry, 2002, 39, 231-236.	0.8	37
98	Spot urine analysis: acidification does not increase calcium recovery. Annals of Clinical Biochemistry, 2002, 39, 64-65.	0.8	4
99	Review of a pilot quality-assessment program for interpretative comments. Annals of Clinical Biochemistry, 2002, 39, 250-260.	0.8	24
100	Hypercalcemia Differential Diagnosis and Investigation. Clinical Reviews in Bone and Mineral Metabolism, 2002, 1, 11-24.	1.3	4
101	Preanalytical factors in the measurement of intact parathyroid hormone with the DPC IMMULITE assay. Clinical Chemistry, 2002, 48, 566-7.	1.5	6
102	Parathyroid hormone is more stable in EDTA plasma than in serum. Clinical Chemistry, 2002, 48, 766-7.	1.5	8
103	Clinical and biochemical features, molecular diagnosis and long-term management of a case of cerebrotendinous xanthomatosis. Clinica Chimica Acta, 2001, 306, 63-69.	0.5	26
104	Measuring myocardial damage. Medical Journal of Australia, 2001, 174, 163-164.	0.8	1
105	Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. Aids, 2001, 15, 1275-1280.	1.0	154
106	Bisphosphonates: an overview with special reference to alendronate. Annals of Clinical Biochemistry, 2001, 38, 608-623.	0.8	104
107	Câ€reactive protein: a new cardiovascular risk factor?. Medical Journal of Australia, 2000, 173, 117-118.	0.8	4
108	Vitamin D insufficiency and hyperparathyroidism in Perth blood donors. Medical Journal of Australia, 2000, 172, 406-407.	0.8	22

#	Article	IF	Citations
109	Therapeutic efficiency of tirofiban in acute coronary syndromes. Lancet, The, 2000, 355, 929-930.	6.3	6
110	Alendronate in the treatment of Paget's disease of bone. Bone, 1997, 20, 263-271.	1.4	44
111	Elimination and Biochemical Responses to Intravenous Alendronate in Postmenopausal Osteoporosis. Journal of Bone and Mineral Research, 1997, 12, 1700-1707.	3.1	247
112	Methylenetetrahydrofolate Reductase Gene and Coronary Artery Disease. Circulation, 1997, 95, 21-23.	1.6	139
113	Sustained response to intravenous alendronate in postmenopausal osteoporosis. Bone, 1995, 17, 517-520.	1.4	32
114	The effects of intravenous alendronate in Paget's disease of bone. Journal of Bone and Mineral Research, 1995, 10, 1094-1100.	3.1	27
115	Secondary hypoadrenalism presenting with hypercalcaemia. Clinical Endocrinology, 1994, 41, 261-264.	1.2	63
116	The effect of alendronate on renal tubular reabsorption of phosphate. Bone and Mineral, 1994, 27, 51-56.	2.0	7
117	Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate. British Journal of Cancer, 1993, 67, 560-563.	2.9	77
118	The assessment of vertebral deformity: A method for use in population studies and clinical trials. Osteoporosis International, 1993, 3, 138-147.	1.3	503
119	Lead poisoning due to traditional herbal preparations. Medical Journal of Australia, 1993, 158, 292-292.	0.8	2